Video

Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)—positive, HER2-negative advanced breast cancer.

<<<

View more from the 2016 ASCO Annual Meeting

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Eric Winer, MD
Aditya Bardia, MD, MPH, FASCO
2 experts are featured in this series.
2 experts are featured in this series.
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine